Agate Medical Investments:
Agate Medical Investments LP is one of Israel's leading investors in advanced stage healthcare companies.
The Fund invested primarily in Israeli and Israel-related, medical device companies and in specialized healthcare services clinics. The fund is led by prominent and highly-experienced investments professionals with extensive medical investments knowledge and healthcare track record.
Founded in 2007, and since has been successfully implementing its strategy of mitigated risk profile investments. the fund is invested in 5 companies and exited 2.
Dani Naveh- Founder
Ariel Moses- Managing Partner
Portfolio – Exits
A global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). Invested: 2009
Exit: February 2014: IPO on NASDAQ (cap $400m). May 2015 M&A by the Chinese XIO group (cap $517m).
Iscare B.V Medical Centers In the Czech Republic and Slovakia specializing in: assisted reproduction; complex treatment of obesity; gastroenterology and treatment of idiopathic intestinal inflammations and plastic surgery. Invested: 2008
Exit: January 2015: M&A by Private Equity fund.
Valeritas is a medical technology company committed to the development and commercialization of innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. The Valeritas medical technologies portfolio is headlined by the h-Patch™ technology. The V-Go Disposable Insulin Delivery Device, designed for the simple delivery of basal-bolus insulin therapy via a preset basal rate and on-demand bolus dosing around mealtimes, is the first use of the h-Patch™ technology.
Portfolio under management
Sensimed AG, a Swiss company, has developed a unique non-invasive soft contact lens-based solution, the SENSIMED Triggerfish®, with the aim of revolutionizing glaucoma management by providing an automated recording of continuous ocular dimensional change over 24 hours.
The Company is now focused on expanding the knowledge of how this individual data can best be used in the clinical setting to deliver customized treatment. The 24-hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment.
Tulip Medical develops the next generation device solution for the worldwide overweight and obesity epidemic. Tulip's breakthrough solution is a unique orally administered biodegradable device pill for supporting weight loss. Its proprietary mechanism of action is designed to create early satiety signaling from the stomach to the brain. The daily use pill is safe, manufactured from FDA approved materials, simple to administer and free of the severe complications associated with existing solutions, targeted to overweight & moderately obese patients. Tulip operates from its headquarters in Herzliya Pituach.
Angioslide Ltd. is a developer of innovative angioplasty balloon catheters that combine balloon angioplasty and debris removal in a single device. Their first product, the Extra Catheter, addresses the developing market of the peripheral vascular diseases, which include – lower limb, iliac, renal and carotid.
BrainsGate is a developer of a novel therapeutic platform based on electrical neurostimulation of the Spheno-Palatine Ganglion (SPG). BrainsGate's leading indication is acute ischemic stroke with a 24-hour treatment window. Additional applications for the treatment of central nervous system disorders include Vascular Dementia and Drug Delivery to the CNS. BrainsGate is headquartered in Caesarea, Israel.
Menachem Begin St. 37
Tel: +972 3 565 2285